Harmony Biosciences rises after quarterly results beat
View all comments(0)
Shares of rare neurological disease-focused pharma company Harmony Biosciences rise HRMY.O 3.5% to $31 premarket
HRMY posts Q1 adj. profit of 78 cents per share, above analysts' estimate of 58 cents per share - data compiled by LSEG
Company posts Q1 product revenue of $184.73 million, beating analysts' estimate of $182.9 million
Company maintains its 2025 product revenue of $820 million to $860 million compared with estimates of $839.89 million
As of last close, HRMY has fallen 12.9% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.